RadNet, Inc. (NASDAQ: RDNT) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), RadNet, Inc. had a Maz Rating of 3.05 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Profitability (4.64), among the strongest in its sector; its weakest was Valuation (1.71), more expensive than most of its sector. The other factors: Growth 4.05 (above most of its sector); Momentum 3.11 (around the middle of its sector); Financial Health 1.72 (below most of its sector). The current rating is for members: log in to see it.
At $76.00, RadNet, Inc. trades at 2.7x sales and 5.5x book value, with an EV/EBITDA of 26.8. Over the last twelve months it generated about $2.2B of revenue and a net loss of $20M. It runs a gross margin of 9.7%, an operating margin of 4.0% and a net margin of -0.9%. It shows return on equity of -2.0%, return on invested capital of 1.4% and a free cash flow yield of -1.0%. On the balance sheet: a debt-to-equity ratio of 1.99 and a current ratio of 1.48. Over the past 52 weeks the share price ranged from $50.82 to $85.84, with a beta of 1.41.
RadNet, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 1 Strong Buy, 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.